Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.

China's low birth rate and aging population are ending any hopes Beijing had of overtaking the U.S. as an economic giant.

GUANGZHOU, China ... in the central nervous system (CNS) and autoimmune fields. Leveraging its proprietary Drug Studio AI platform, Fermion prioritizes high target selectivity and tissue targeting ...

But then the target bank ran low ... said he still believes militaries in the West must embrace AI tools to combat rivals such as China, but he worries about the accuracy of AI-enabled decision ...

Cyber Insights 2025 examines expert opinions on the expected evolution of more than a dozen areas of cybersecurity interest over the next 12 months. We spoke to hundreds of individual experts to gain ...

Anduril, a military drone start-up with links to Trump’s tech advisers, says U.S. military power needs rebuilding around ...

The collision between AI-generated imagery and consumer expectations fueled human frustrations in February when Scottish families discovered that "Willy's Chocolate Experience," an unlicensed ...

The Global Equity composite fell 0.86% gross of fees in the fourth quarter, in line with the 0.89% decline of the MSCI ACWI ...

A man who taped a sinister note to a Chinese ex-official’s door in New Jersey was sentenced Wednesday to 16 months in prison.

Scaling personalized therapies brings unique logistical challenges. Unlike mass-market drugs, these treatments require highly ...

JPMorgan’s Global CISO Pat Opet discusses overcoming cyber regulatory fragmentation and securing a broadening supply chain in ...